» Articles » PMID: 20668041

Down-regulation of Wee1 Kinase by a Specific Subset of MicroRNA in Human Sporadic Pituitary Adenomas

Overview
Specialty Endocrinology
Date 2010 Jul 30
PMID 20668041
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Context: The tumorigenic mechanisms involved in pituitary adenomas, especially of nonfunctional pituitary adenomas (NFAs), remains unclear. Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors.

Objective: Our objective was to examine the expression of Wee1 in pituitary tumors and to identify microRNAs (miRs) that can regulate its expression.

Design: Expression of Wee1 was examined by immunohistochemistry and quantitative real-time PCR (qRT-PCR). Identification of miRs targeting the Wee1 3'-untranslated region was performed by miR array followed by expression analysis of identified miRs using qRT-PCR. Dual-luciferase assay and transient transfection of miRs into Hela cells followed by immunoblot analysis of Wee1 protein and cell proliferation analysis were carried out.

Patients: A total of 57 pituitary tissue samples including 27 NFAs, 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands were analyzed.

Results: Wee1 protein expression was decreased in NFAs and GH-producing tumors with or without prolactin production, but no change in mRNA expression was observed with qRT-PCR. A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation.

Conclusions: To our knowledge, this is the first report suggesting that regulation of Wee1 kinase by miRs may be linked to pituitary tumorigenesis.

Citing Articles

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.

Whyte E, Nezu M, Chik C, Tateno T Endocrinol Metab (Seoul). 2023; 38(6):631-654.

PMID: 37964483 PMC: 10764990. DOI: 10.3803/EnM.2023.1838.


Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders.

Alli V, Yadav P, Suresh V, Jadav S ACS Omega. 2023; 8(23):20196-20233.

PMID: 37323408 PMC: 10268025. DOI: 10.1021/acsomega.3c01558.


A novel risk model based on the correlation between the expression of basement membrane genes and immune infiltration to predict the invasiveness of pituitary adenomas.

Chen Z, Sun X, Kang Y, Zhang J, Jia F, Liu X Front Endocrinol (Lausanne). 2023; 13:1079777.

PMID: 36686480 PMC: 9846255. DOI: 10.3389/fendo.2022.1079777.


Modulation of the long non-coding RNA Mir155hg by high, but not moderate, hydrostatic pressure in cartilage precursor cells.

Montagne K, Furukawa K, Taninaka Y, Ngao B, Ushida T PLoS One. 2022; 17(12):e0275682.

PMID: 36538560 PMC: 9767356. DOI: 10.1371/journal.pone.0275682.


Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma.

Wu W, Cao L, Jia Y, Xiao Y, Zhang X, Gui S Cells. 2022; 11(18).

PMID: 36139495 PMC: 9496700. DOI: 10.3390/cells11182920.